Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

ChIP-seq of H3K9ac and H3K14ac in U87 glioma cells treated with differentiation agents(0.5mM 8-cpt-cAMP combined with 1nM MS275) for 48h

ABSTRACT: ChIP-seq of H3K9ac and H3K14ac in U87 glioma cells treated with differentiation agents(0.5mM 8-cpt-cAMP combined with 1nM MS275) for 48h

PROVIDER: PRJNA664703 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR12682187.fastq.gz	Fastqsanger.gz
	SRR12682188.fastq.gz	Fastqsanger.gz
	SRR12682189.fastq.gz	Fastqsanger.gz
	SRR12682190.fastq.gz	Fastqsanger.gz
	SRR12682191.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 6

Similar Datasets

RNAseq of U87 treated with bulk control/0.5mM 8-cpt-cAMP/1nM MS275 or a combination

Project description:Transcriptomics revealed that the combination of 8-cpt-cAMP and MS275 could maximize the glioma differentation compared to control or use either drug alone

2023-03-15 | GSE158015 | GEO

RNAseq of U87/over-expressed DPF3 U87 treated with bulk control/0.5mM 8-cpt-cAMP combination with 1nM MS275 for 48hrs

Project description:Transcriptomics revealed that the combination of 8-cpt-cAMP and MS275 could maximize the glioma differentation compared to control or use either drug alone

2020-09-17 | GSE158065 | GEO

RNAseq and the histone acetylated chromosome immunoprecipitation of U87 or GBM stem cells(GSC) treated with bulk control/0.5mM 8-cpt-cAMP/1nM MS275 or a combination

Project description:Transcriptomics and the ChIP-seq revealed that the combination of 8-cpt-cAMP and MS275 could maximize the glioma differentation compared to control or use either drug alone

2022-10-17 | GSE215401 | GEO

RNAseq of U87 treated with bulk control/0.5mM 8-cpt-cAMP/1nM MS275 or a combination

Project description:RNAseq of U87 treated with bulk control/0.5mM 8-cpt-cAMP/1nM MS275 or a combination

| PRJNA663633 | ENA

RNAseq of U87/over-expressed DPF3 U87 treated with bulk control/0.5mM 8-cpt-cAMP combination with 1nM MS275 for 48hrs

Project description:RNAseq of U87/over-expressed DPF3 U87 treated with bulk control/0.5mM 8-cpt-cAMP combination with 1nM MS275 for 48hrs

| PRJNA663874 | ENA

ChIP-seq of H3K9ac and H3K14ac in U87 glioma cells treated with differentiation agents(0.5mM 8-cpt-cAMP combined with 1nM MS275) for 48h

Project description:We report the diverse histone acetylation pattern on histone 3 lysine 9 and lysine14 under the cell differentiation. The genes controlled by this two histone acetylation modification can transformed the cell identity of the glioma by downregualted the promoter of oncogenes' H3K9 acetyltion and improve the promoter of neuron-differentiation related genes' H3K14 acetylation

2020-09-22 | GSE158272 | GEO

RNAseq and the histone acetylated chromosome immunoprecipitation of U87 or GBM stem cells(GSC) treated with bulk control/0.5mM 8-cpt-cAMP/1nM MS275 or a combination

Project description:RNAseq and the histone acetylated chromosome immunoprecipitation of U87 or GBM stem cells(GSC) treated with bulk control/0.5mM 8-cpt-cAMP/1nM MS275 or a combination

| PRJNA890206 | ENA

Transcriptome analysis of novel CPT-CEF-treated HT29 colon cancer cells to evaluate drug cytotoxicity

Project description:Purpose: To identify differentially expressed genes in HT29 colon cancer cells after treatment with a novel formulation of camptothecin with β-cyclodextrin-EDTA-Fe3O4 nanoparticle-conjugated nanocarriers (CPT-CEF) Methods:Treated HT29 cell lines with CPT-CEF, isolated total RNA from HT29 colon cancer cells, and prepared library for RNA sequencing. Carried out comparative transcriptomic studies between treated and untreated cells to find out which gene functions were dysregulated by CPT-CEF. Results: The study yielded 247 DEGs ((FDR<0.05, FC>2.0) that were affected by CPT-CEF treatment in the HT29 colon cancer cells. The results obtained from cell cycle analysis, mitochondrial depolarization assay and acridium orange/propidium iodide double staining showed potential of CPT-CEF in cancer cell inhibition. Conclusion: Our study successfully identified DEGs in the CPT-CEF treated HT29 colon cancer cells that pointed to inhibition of cancer progression. To further affirm, animal studies are needed.

2021-09-15 | GSE165875 | GEO

SPT6 Regulates H3K14Ac Deposition in Mouse Embryonic Stem Cells [PRO-seq]

Project description:SPT6 (suppressor of Ty 6) is a conserved histone chaperone that facilitates transcription elongation, nucleosome reassembly, and RNA polymerase II progression. The functions of SPT6 in regulating chromatin remain not fully understood. Here we show that SPT6 localized to H3K14Ac enriched regions and promoted H3K14Ac densities in mouse embryonic stem cells (mESCs). Loss of SPT6 results in decreased H3K14Ac and transcription. Mechanistically, we showed that SPT6 enhances the chromatin binding levels of acetyltransferases KAT7 and KAT6A/KAT6B. In addition, we showed that SPT6 also promotes H3K14Ac in a KAT7/6A/6B independent manner. Our findings identify a vital role of SPT6 in maintaining the integrity of H3K14Ac profile in mESCs, thus suggesting a crosstalk between transcription machinery and H3K14Ac in mammals.

2025-05-22 | GSE282181 | GEO

SPT6 Regulates H3K14Ac Deposition in Mouse Embryonic Stem Cells [RNA-seq]

2025-05-22 | GSE282180 | GEO